Quantcast
Last updated on April 24, 2014 at 21:24 EDT

TheraSphere(R) Providing Hope to Liver Cancer Patients in Turkey

February 16, 2012

Leading Istanbul hospital will host news conference to educate public
about a safe, well-tolerated and innovative treatment

ISTANBUL, Turkey, Feb. 17, 2012 /PRNewswire/ – Nordion Inc. (TSX: NDN) (NYSE:
NDZ), a leading provider of products and services to the global health
science market, today celebrated the first anniversary of the market
introduction of TheraSphere(1), an innovative radioembolic liver cancer therapy, in the Republic of
Turkey. The first treatment was administered in Ankara in December
2010. Since then, more than 80 patients have undergone the treatment in
more than a half-dozen private and public hospitals across the country.

TheraSphere, available in 16 countries around the world, is a targeted
liver cancer therapy consisting of millions of tiny glass beads, each
smaller than the diameter of a human hair, containing yttrium-90
(Y-90). In Turkey, it is approved to treat both hepatocellular
carcinoma (HCC), a form of primary liver cancer, and metastatic liver
cancer (cancer that has spread to the liver from another point of
origin).

To mark the anniversary, a news conference is being held today at
Acibadem Maslak Hospital, a state-of-the-art private hospital in
Istanbul with a strong specialization in cancer treatment. Physicians
and Nordion representatives will provide information and demonstrations
on how radioembolic therapy works, how it is administered, and what
patients undergoing treatment can expect.

Dr. Riad Salem, Professor of Radiology, Medicine and Surgery and
Director, Interventional Oncology at Northwestern University in
Chicago, is attending the news conference and will present the point of
view of a doctor who has been a long-standing researcher and clinician
applying this treatment in patients with liver cancer.

“This novel treatment allows me to target radiation directly at the
tumour from inside the body, and limits damage to the healthy
surrounding tissue,” said Dr. Salem. “The procedure can be performed in
about one hour, the patients often go home the same day, and studies
have shown that side effects are usually not as severe as with other
treatments. Quality of life and comfort are very important to patients
with this disease and to their families.”

According to GLOBOCAN, the World Health Organization (WHO)’s agency for
cancer data and research, more than 1,090 new cases of primary liver
cancer were diagnosed in men and women in Turkey in 2008, with
approximately 1,050 deaths from primary liver cancer that same year. In
addition, approximately 60 percent of colorectal cancer (CRC) patients
will develop liver metastases, and more than 7,200 new cases of CRC
were diagnosed in Turkey in 2008.

“Nordion made a strategic decision to launch TheraSphere in Turkey last
year and our commercial efforts, together with those of our Turkish
distributor, Eczacibasi Monrol Nuclear Products, mean more physicians
in the region are aware and now have access to this innovative
treatment, to the benefit of their patients,” said Kevin Brooks,
Nordion’s Senior Vice President of Sales and Marketing. “The clinical
adoption we have seen in Turkey over the past 12 months supports our
decision to expand into this market, and clearly demonstrates a strong
clinical interest in TheraSphere.”

The therapy is currently available at the following hospitals in Turkey:

        --  Istanbul University Cerrahpa_a Medicine Faculty (Istanbul)
        --  Hacettepe University (Ankara)
        --  Gazi University (Ankara)
        --  American Hospital (Istanbul)
        --  Istanbul Memorial Hospital (Istanbul)
        --  Acibadem Maslak Hospital (Istanbul)

About TheraSphere
TheraSphere is a liver cancer therapy that consists of millions of small
glass beads (20 to 30 micrometers in diameter) containing radioactive
yttrium-90. The product is injected by physicians into the main artery
of the patient’s liver through a catheter, which allows the treatment
to be delivered directly to the tumour via blood vessels.  Nordion is
approved (CE Mark) in Europe to distribute TheraSphere for treatment of
hepatic neoplasia. Nordion established a European TheraSphere Centre of
Excellence in Essen, Germany to train and educate oncology
professionals on the use of this innovative cancer treatment. In
addition, there are multiple treatment centres across Europe, including
the BCLC Group Hospital Clinic in Barcelona, Spain; Centre Eugène
Marquis in Rennes, France; and Istituto Tumori in Milan, Italy. In the
U.S., TheraSphere is currently approved by the U.S Food and Drug
Administration (FDA) under a Humanitarian Device Exemption (HDE) for
treatment of unresectable hepatocellular carcinoma (HCC). TheraSphere
has some common side effects, including mild to moderate fatigue, pain
and nausea. Physicians describe these symptoms as similar to those of
the common flu. Some patients will experience some loss of appetite and
temporary changes in several blood tests. For more information on
TheraSphere, please visit www.nordion.com/TheraSphere.

About Nordion Inc. 
Nordion Inc. (TSX: NDN) (NYSE: NDZ) is a global health science company
that provides market-leading products used for the prevention,
diagnosis and treatment of disease. We are a leading provider of
medical isotopes, targeted therapies and sterilization technologies
that benefit the lives of millions of people in more than 60 countries
around the world. Our products are used daily by pharmaceutical and
biotechnology companies, medical-device manufacturers, hospitals,
clinics and research laboratories. Nordion has more than 500 highly
skilled employees in three locations. Find out more at www.nordion.com and follow us at http://twitter.com/NordionInc.

(1) TheraSphere is a trademark of Theragenics Corporation used under
license by Nordion (Canada) Inc. Please note that TheraSphere is an
unregistered trademark in Turkey.

SOURCE Nordion Inc.


Source: PR Newswire